biosimilaradj.n.
/ˌbʌɪəʊˈsɪm(ᵻ)lə/, U.S. /ˌbaɪoʊˈsɪm(ə)lər/ Medicine.
A. adj.
Of a biopharmaceutical, esp. one produced by recombinant DNA technology: designed to have active properties similar to those of a previously licensed biopharmaceutical. Cf. biogeneric adj.
ΘΚΠ
the world > health and disease > healing > medicines or physic > [adjective] > other qualities of medicines
lighteOE
emphractic1659
concentrant1721
potentized1851
antiperiodic1861
weak1899
stathmokinetic1939
bioavailable1973
biosimilar2002
2002 European Drug Rep. 4 Nov. 2/2 Biosimilar products—those having the same physico-chemical and biological properties and pharmaceutical form as the brand drug.
2009 H. Schellekens in S. G. Elliott et al. Erythropoietins, Erythropoietic Factors, & Erythropoiesis (ed. 2) 111 Alpheon, a biosimilar version of Roferon-A (IFN alfa-2a), was rejected by the EMEA.
2011 N.Y. Times (Nexis) 20 Dec. b6 Amgen has plans for other biosimilar drugs.
B. n.
A biosimilar drug. Cf. biogeneric n.
ΚΠ
2003 Pharma Marketletter (Nexis) 6 Oct. To be approved, ‘biosimilars’ must undergo a re-clinical testing and clinical trials procedure which is different from..generic versions of chemical drugs.
2013 M. Osmane Rift-lines European Regulatory Framework for Biosimilars vi. 210 The biosimilar..must show independent safety for patients by clinical trials.
This is a new entry (OED Third Edition, June 2014; most recently modified version published online December 2021).
<
adj.n.2002